Atopic dermatitis: emerging therapies

Semin Cutan Med Surg. 2017 Sep;36(3):124-130. doi: 10.12788/j.sder.2017.0137.

Abstract

Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.

Publication types

  • Review

MeSH terms

  • Anisoles / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antipruritics / therapeutic use
  • Boron Compounds / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
  • Dermatitis, Atopic / drug therapy*
  • Dermatitis, Atopic / prevention & control
  • Dermatologic Agents / therapeutic use*
  • Emollients / therapeutic use
  • Humans
  • Infant
  • Infant Formula
  • Interleukin-13 / antagonists & inhibitors
  • Interleukin-4 / antagonists & inhibitors
  • Nitriles / therapeutic use
  • Phosphodiesterase 4 Inhibitors / therapeutic use
  • Phthalic Acids / therapeutic use
  • Probiotics / therapeutic use
  • Quinazolines / therapeutic use

Substances

  • Anisoles
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antipruritics
  • Boron Compounds
  • Bridged Bicyclo Compounds, Heterocyclic
  • Dermatologic Agents
  • Emollients
  • IL13 protein, human
  • IL4 protein, human
  • Interleukin-13
  • MM 36
  • Nitriles
  • Phosphodiesterase 4 Inhibitors
  • Phthalic Acids
  • Quinazolines
  • methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate
  • Interleukin-4
  • dupilumab
  • crisaborole